{"id":1076,"date":"2021-05-31T06:49:55","date_gmt":"2021-05-31T06:49:55","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=1076"},"modified":"2021-05-31T06:49:55","modified_gmt":"2021-05-31T06:49:55","slug":"28-may-2021-sotrovimab-85-reduction-in-progression-of-covid-19-in-patients-with-mild-moderate-disease","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/28-may-2021-sotrovimab-85-reduction-in-progression-of-covid-19-in-patients-with-mild-moderate-disease\/","title":{"rendered":"(28 May 2021) Sotrovimab- 85% reduction in progression of Covid-19 in patients with mild\/moderate disease"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab<\/p>\n<p>https:\/\/www.medrxiv.org\/content\/10.1101\/2021.05.27.21257096v1<\/p>\n<p class=\"\">NCT04545060-In this preplanned interim analysis, which included an intent-to-treat population of 583 patients (sotrovimab, 291; placebo, 292), the primary efficacy endpoint was met. The risk of Covid-19 progression was significantly reduced by 85% (97.24% confidence interval, 44% to 96%; P = 0.002) with a total of three (1%) patients progressing to the primary endpoint in the sotrovimab group versus 21 (7%) patients in the placebo group. All five patients admitted to intensive care, including one who died by day 29, received placebo. Safety was assessed in 868 patients (sotrovimab, 430; placebo, 438). Adverse events were reported by 17% and 19% of patients receiving sotrovimab and placebo, respectively; serious adverse events were less common with sotrovimab (2%) versus placebo (6%).&nbsp;Sotrovimab reduced progression of Covid-19 in patients with mild\/moderate disease, was well tolerated, and no safety signals were identified.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Early Covid-19 Treatment With SARS-CoV-2 Neutralizing Antibody Sotrovimab https:\/\/www.medrxiv.org\/content\/10.1101\/2021.05.27.21257096v1 NCT04545060-In this preplanned interim analysis, which included an intent-to-treat population of 583 patients (sotrovimab, 291; placebo, 292), the primary efficacy endpoint was met. The risk of Covid-19 progression was significantly reduced&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/28-may-2021-sotrovimab-85-reduction-in-progression-of-covid-19-in-patients-with-mild-moderate-disease\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(28 May 2021) Sotrovimab- 85% reduction in progression of Covid-19 in patients with mild\/moderate disease&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,145],"tags":[146],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1076"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=1076"}],"version-history":[{"count":2,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1076\/revisions"}],"predecessor-version":[{"id":1078,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/1076\/revisions\/1078"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=1076"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=1076"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=1076"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}